- This partnership is set to enhance the treatment options available to diabetes patients in Brazil. Under the agreement, Biocon will be responsible for the development, manufacturing, and supply The post Biocon signs licensing and supply...
- A product of BioCryst Pharmaceuticals, Orladeyo’s registration, commercialisation and distribution are solely handled by Pint Pharma in Latin America. Hereditary angioedema (HAE) is a genetic disorder characterised by The post Orladeyo...
- The designation is specifically for the characterisation of progressive or recurrent glioma using positron emission tomography (PET). TLX101-CDx is a PET imaging agent that targets membrane transport proteins The post Telix...
- The company also plans to implement additional measures. This decision comes as the company seeks to extend its cash runway available and reassess its capital raising options in The post Immuno-oncology company Portage Biotech to...
- This partnership follows the US Food and Drug Administration’s approval of ADSTILADRIN in December 2022 for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) The...
- A novel approach to drug discovery is enabling University of Birmingham researchers to overcome the 'valley of death', where projects fail due to the funding gap between original research and commercial investment. The approach, detailed...
- Alzheimer's disease (AD) currently afflicts nearly seven million people in the U.S. With this number expected to grow to nearly 13 million by 2050, the lack of meaningful therapies represents a major unmet medical need. Scientists at...
- Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, on Sunday April 14 presented results from the 18-month Phase Ib clinical trial for...
- Antisense oligonucleotides (ASOs) are next-generation drugs that can treat disease by blocking the transfer of harmful messages from our genes. In people with cancer, ASOs have the potential to block messages that encourage the growth...
- The recommendation, detailed in the final draft guidance, specifically targets patients whose B-cell ALL has been resistant to treatment, has recurred post stem-cell transplant, or has relapsed for The post NICE recommends Novartis’...
- Researchers have developed a functional precision medicine approach that targets cancer by combining genetic testing with a new way to test individual drugs on tumor samples. The results of the clinical study were published today in...
- Thiazolidinediones (TZDs) are a class of drug that can be used to treat type 2 diabetes by reversing insulin resistance, one of the main hallmarks of the disease. While TZDs were extremely popular in the 1990’s and early 2000’s, they...
- The funding will be used for the advancement of TORL’s new antibody-drug conjugate (ADC) oncology pipeline, including the clinical development. The Series B-2 financing was led by Deep The post TORL BioTherapeutics secures $158m for...
- This collaboration aims to harness Invenra’s B-Body bispecific antibody platform to advance Astellas’ research and development in antibody discovery. Invenra CEO Dr Roland Green said: “We are honoured The post Invenra,...
- This approval introduces a once-daily, oral, two-drug regimen for individuals aged 12 years and above, weighing a minimum of 25kg. Dovato, which combines dolutegravir (50mg) with lamivudine (300mg), The post FDA approves ViiV...
- This designation is based on results from the global multi-center Phase I/II study, WU-KONG1. The BTD was awarded following the presentation of results at the 2023 ESMO conference, The post US FDA grants breakthrough status to Dizal’s...
- Infection with the influenza virus leads to lung injury through inflammation over-activation that causes collateral damage to cells required for breathing. Such damage can be life-threatening, but scientists have a new preventative...
- Swapping red meat for 'forage fish', such as herring, sardines, and anchovies, could save up to 750,000 lives a year in 2050 and significantly reduce the prevalence of disability as a result of diet-related disease, suggests a data...
- A new study by Upstate Medical University researchers shows that recreational cannabis use may offer protection against cognitive decline. The study, done by Master of Public Health (MPH) student Zhi Chen and Professor Roger Wong, Ph.D.,...
- The lab of Yongchao C. Ma, PhD, at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago discovered a fundamental biological mechanism that could lead to new treatments for neurological...
- The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive activation and cytokine-independent...
- A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at...
- Changes in the gut microbiome have been implicated in a range of diseases including type 2 diabetes, obesity, and inflammatory bowel disease. Now, a team of researchers at the Broad Institute of MIT and Harvard along with Massachusetts...
- Mayo Clinic scientists have developed an immunotherapy strategy that potentially lays the groundwork for treating a spectrum of autoimmune diseases. The new technique, detailed in a preclinical study published in Nature Biomedical...
- A transformative study published in Health Data Science, a Science Partner Journal, introduces a groundbreaking end-to-end deep learning framework, known as Knowledge-Empowered Drug Discovery (KEDD), aimed at revolutionizing the field of...
- Implementing a single shared digital prescribing record across the NHS in England could avoid nearly 1 million drug errors every year, stopping up to 16,000 fewer patients from being harmed, and saving up to 22 lives every year, suggests...
- A ground-breaking study - the largest of its kind globally - has found children with multiple sclerosis (MS) have better outcomes if treated early and with the same high-efficacy therapies as adults. There are a limited number of...
- The U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older. Duvyzat is the first nonsteroidal drug approved to treat...
- Some anti-cancer treatments not only target tumour cells but also healthy cells. If their effects on the latter are too strong, their use can become limiting. A team from the University of Geneva (UNIGE), in collaboration with...
- An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic benefit in a clinical trial led by the...
- The inflammatory disease affects around one in 2,000 people in the US
- Results from a mid-stage of the candidate were recently published in the NEJM
- The skin disease affects an estimated 1% of the population in most studied countries
- The collaboration will first focus on developing products for long COVID and ME/CFS
- Researchers used a technique to identify specific molecular details of biotin-labelled proteins
- Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year
- The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals
- The drug could prevent conditions including diabetic eye and kidney disease in diabetes
- The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban
- The deal gives the company access to a candidate being evaluated in primary biliary cholangitis
- There are now more than 8,000 patients who are potentially eligible for treatment with Casgevy
- Approximately one in 10,000 people are affected by the genetic blood clotting disorder
- The rare genetic disorder is estimated to affect around one in every 40,000 people in the UK
- F404 mutations combined with pre-existing mutations caused resistance to fulvestrant
- Both companies will leverage their autologous CAR-T cell therapy programmes
- Ten23 health expands former swissfillon facility in Visp, Switzerland jkeenan Mon, 03/28/2022 - 08:41
- Sobi to trim staff as Pfizer manufacturing contract ends early jkeenan Thu, 03/24/2022 - 08:40
- Epinephrine recall: Adamis pulls Symjepi injections for needle clogging risks aliu Wed, 03/23/2022 - 11:18
- Fujifilm makes yet another deal to jack up cell and gene therapy capacity kdunleavy Tue, 03/22/2022 - 21:13
- Takeda's Natpara relaunch bid falls flat as manufacturing concerns drag on jkeenan Tue, 03/22/2022 - 09:22